The gadopiclenol extension for use in infants and neonates offers high-quality MRI contrast enhancement at half the standard gadolinium dose. The FDA has approved an extension of intravenous ...

Nontargeted testing identified 42 PFAS in cord blood, far exceeding the 8 compounds measured by traditional targeted methods, suggesting broader prenatal exposure. Cumulative exposure estimates ...

Sustained functional benefit through 3 years: In ambulatory patients with Duchenne muscular dystrophy, ELEVIDYS maintained NSAA scores above baseline and slowed decline on timed function tests (TTR ...

Findings from phase 3 SHORE and COAST 2 trials showed amlitelimab met key efficacy end points in moderate to severe atopic dermatitis, supporting planned regulatory submissions. Sanofi announced ...

Clinicians now have the first oral alternative to injectable therapy for gonorrhea, a shift Angela Hasler, APRN, CPNP-PC says could ease treatment barriers and improve public health outcomes.

FDA approves Itvisma for patients 2 years and older with SMA, making it the first FDA-approved gene replacement therapy for this population. FDA approved Itvisma as the first gene replacement therapy ...

Newborn guidance emphasizes preparation, team training, and extended delayed cord clamping. The guidelines include new and revised recommendations across pediatric basic and advanced life support and ...

FDA accepts MannKind’s sBLA for Afrezza in children and adolescents with diabetes. The FDA has accepted MannKind Corporation’s sBLA to expand the indication of Afrezza (insulin human) Inhalation ...

The Committee voted against a proposed recommendation that "state and local jurisdictions should require a prescription for the administration of a COVID-19 vaccination.

Specifically, the ACIP voted 5-2 to recommend clesrovimab (Enflonsia; Merck), which was approved by the FDA on June 9, 2025, for infants aged 8 months and younger who are not protected by a maternal ...

Delandistrogene moxeparvovec-rokl (ELEVIDYS) showed significant motor function improvements in 8- to 9-year-old Duchenne muscular dystrophy patients in part 2 of the phase 3 EMBARK study. In part 2 of ...

Current prevention strategies include 2 injectables for infants and young children, namely palivizumab and nirsevimab. Respiratory syncytial virus (RSV) illness is an extremely common cause of ...